{"id":"pletaal-sr-capsule","safety":{"commonSideEffects":[{"rate":"25–30%","effect":"Headache"},{"rate":"15–20%","effect":"Diarrhea"},{"rate":"5–10%","effect":"Palpitations"},{"rate":"5–10%","effect":"Dizziness"},{"rate":"5%","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL4591082","moleculeType":"Unknown","molecularWeight":"622.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cilostazol is a selective PDE-3 inhibitor that increases intracellular cAMP in platelets and vascular smooth muscle cells, resulting in reduced platelet aggregation and improved blood flow. The sustained-release (SR) formulation provides prolonged therapeutic levels. It is used primarily to improve walking distance in patients with intermittent claudication due to peripheral arterial disease.","oneSentence":"Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:42.287Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermittent claudication due to peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT01711333","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-10-26","conditions":"Chronic Occlusive Arterial Disease","enrollment":101},{"nctId":"NCT01782833","phase":"","title":"Pletaal SR Post Marketing Observational Study","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-01","conditions":"Ischemic Symptoms, Cerebral Infarction","enrollment":3635}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pletaal SR capsule","genericName":"Pletaal SR capsule","companyName":"Korea Otsuka Pharmaceutical Co., Ltd.","companyId":"korea-otsuka-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation. Used for Intermittent claudication due to peripheral arterial disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}